AI assistant
PULSE BIOSCIENCES, INC. — Director's Dealing 2026
Feb 24, 2026
32093_dirs_2026-02-23_99463921-c1d7-4f6e-81f0-0f841c7b68aa.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PULSE BIOSCIENCES, INC. (PLSE)
CIK: 0001625101
Period of Report: 2026-02-18
Reporting Person: Danahy Kevin Patrick (Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-02-18 | Common Stock | M | 5000 | $1.53 | Acquired | 48298 | Direct |
| 2026-02-18 | Common Stock | S | 5000 | $23.64 | Disposed | 43298 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2026-02-18 | Stock Option (right to buy) | $1.53 | M | 5000 | Disposed | 2032-09-23 | Common Stock (5000) | Direct |
Footnotes
F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025.
F2: The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $22.40 to $24.40 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range.
F3: Options granted on September 23, 2022, to acquire up to 450,000 shares of Common Stock, in connection with reporting person's promotion, with 25% vesting on each anniversary of grant, pursuant to the terms of an amendment to reporting person's Employment Agreement dated February 9, 2022.